Breast Cancer Diagnostic System (BDS)

BDS has been developed and tested by the world’s leading breast cancer specialists. It has been developed to make mammograms and all other current breast cancer diagnostic technologies obsolete in the next generation. What separates BDS from mammograms and other leading cancer diagnostic technology is its accuracy level.

BDS technology is far more effective than mammograms and other forms of breast cancer diagnostic technology for a number of reasons including:

Accuracy: BDS can detect up to 30% of cancers (especially small tumours in younger women) missed by current technologies.
Safe & Painless: BDS is non-invasive, painless and radiation free and the procedure may be repeated as frequently as desired thus eliminating unnecessary biopsies, which up until now may have attributed to women not seeking early detection in the first place.
Portability: BDS can be used in a physician’s office and small enough to transport to rural areas creating options for women who cannot visit a hospital or major medical centres for their screenings.
Rapid Results: BDS provide accurate results immediately (15 minutes) and a trained technician rather than a physician or radiologist can perform the procedure.
Cost to patient: BDS is ten times less expensive than mammograms, ultrasound, CT scans and MRIs.
Cost to Physician: BDS is profitable to the physician yet testing can be priced lower than diagnostic mammography and screening mammograms, with no expensive training or other lab fees.
Standalone Screening: Singapore re-analyzed the original US clinical trial data conducted by Biofield and results shows a very good sensitivity, specificity, accuracy and ROC curve (AROC) by different statistical method. This may indicate that BDS need not be dependent on mammogram or ultrasound or physical examination and can be treated as a standalone screening device.

Technology Overview
The state of the Art Technology BDS is a revolutionary patented system for the detection of uncontrolled cellular proliferation that is characteristic of cancer. BDS works by measuring electropotentials in the breast tissue through single-use, disposable Sensors the size of quarters placed on the breasts and connected to a portable briefcase-sized computer device.

Significant electropotential differences in different areas of the breasts are associated with rapid or abnormal growth patterns in the underlying tissue, such as those found in premalignant and malignant lesions. Normal resting breast cells are polarized with the inside about 70mV more negative than the outside of the cell, referred to as the transmembrane potential. All cancer cells are depolarized compared to their homologous normal cells with a transmembrane difference of -55 to -20mV. When cells divide, the polarization decreases. Growth or proliferation and death (apoptosis) of normal cells are highly regulated. Cancers are defined as unregulated rapidly proliferating immortalized cells. Rapidly proliferating cells have increased Na ion permeability. Excess Na ion accumulates in the cell, while K ion decreases. Resting cancer cells are thus depolarized with a more positive electropotential than normal cells. The Goldman principle states that “motion of ions equals electric current.” The transmembrane electropotentials generated by ionic currents have been measured by using microelectrodes inserted through the cell membrane, and aid in the understanding of biopotentials and the nature of the cell processes and functions and correlate with surface measurements, such as the electrocardiogram. What is recorded by skin-surface biopotential measurements, however, is not the transmembrane potential but the signal generated externally from cells, due to the external flow of current from a region of the cell membrane having a higher voltage, to one having a lower voltage; the signal is thus due to the current flow through the conducting medium. If such a signal exists in the steady state, a direct current signal will be generated.

More Accurate Than other Technologies

Procedure
Sensitivity
Specificity
Objective Results
Physical Examination
71% - 86%
20% - 60%
no
Diagnostic Mammography
78% - 90%
20% - 40%
no
Ultrasound
60% - 80%
38% - 74%
no
FNA
65% - 98%
34% - 99%
yes
Biofield
90% - 95%
40% - 65%
yes